Sanofi (NASDAQ:SNY) Stock Rating Upgraded by StockNews.com

Sanofi (NASDAQ:SNY) was upgraded by investment analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Wednesday.

SNY has been the subject of a number of other research reports. Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Argus lifted their price target on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Sanofi has a consensus rating of “Buy” and a consensus price target of $57.50.

Sanofi Trading Down 1.1 %

Shares of NASDAQ:SNY opened at $52.88 on Wednesday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a 52-week low of $45.00 and a 52-week high of $58.97. The stock has a market cap of $134.20 billion, a price-to-earnings ratio of 26.98, a PEG ratio of 1.55 and a beta of 0.60. The business has a 50-day moving average price of $55.98 and a 200-day moving average price of $51.91.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. The business had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 20.59%. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period in the previous year, the business posted $2.55 EPS. Equities analysts predict that Sanofi will post 4.25 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Northwest Investment Counselors LLC purchased a new position in shares of Sanofi in the 3rd quarter valued at about $29,000. POM Investment Strategies LLC purchased a new position in shares of Sanofi during the 2nd quarter valued at approximately $25,000. Concord Wealth Partners grew its stake in Sanofi by 157.8% in the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after acquiring an additional 363 shares during the period. Larson Financial Group LLC increased its holdings in Sanofi by 480.8% in the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock worth $29,000 after acquiring an additional 500 shares in the last quarter. Finally, Palisade Asset Management LLC acquired a new position in Sanofi during the first quarter worth $31,000. Institutional investors and hedge funds own 10.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.